Notably, the sensitivity of 18FDG-PET for HCC is lower than for other malignant cancers [20, 21], which suggests 18FDG (−) HCC does not overexpress SLC2A1 and SLC2A3. This evidence concerns the gene SLC2A1 and hepatocellular carcinoma.